Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study

J Am Acad Dermatol. 2020 Jun;82(6):1530-1532. doi: 10.1016/j.jaad.2020.02.029. Epub 2020 Feb 16.

¹ Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
² Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
³ Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁴ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada.
⁵ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Probity Medical Research Inc, Waterloo, Ontario, Canada. Electronic address: jensen.yeung@utoronto.ca.

No abstract available

Publication types